Priority Lists
Protocol Posting of
Activations
A Phase I Study of Tirapazamine/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
| Study Coordinator(s) | Quynh-Thu X. Le, M.D., Stephen K. Williamson, M.D., Janice Ryu, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Radiation Oncologists |
A Randomized Phase III Trial of ICE Chemotherapy With or Without Rituximab for the Treatment of Relapsed or Refractory CD20 Expressing Agressive B-Cell Non-Hodgkin's Lymphomas in Patients Not Suitable for High Dose Therapy and PBSCT.
| Study Coordinator(s) | David G. Maloney, M.D.,Ph.D., Thomas P. Miller, M.D., Thomas M. Grogan, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists |
Closures
Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma, Phase III
| Study Coordinator(s) | Steven M. Grunberg, M.D., Jamshid Ahmadi, M.D., Jeannette J. Townsend, M.D. |
| Participants | NCORP, Members |
| Closure Date | 1998-07-01 |
Amendments, Revisions, Memoranda
A Phase III Study of Doxorubicin-Cyclophosphamide Therapy Followed by Paciltaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients with Axillary Node-Positive or High-Risk Node Negative Breast Cancer
| Study Coordinator(s) | Silvana Martino, D.O. |
| Participants | Members, Medical Oncologists, Pathologists, NCORP, Surgeons |
A Comparison of Intensive Sequential Chemotherapy using Doxorubicin plus Paclitaxel plus Cyclophosphamide with High Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Support for Primary Breast Cancer in Women with >= 4 Involved Axillary Lymph Nodes, Phase III, Intergroup.
| Study Coordinator(s) | Scott I. Bearman, M.D., William P. Peters, M.D.,Ph.D., Lori J. Pierce, M.D. |
| Participants | Members, Medical Oncologists, Radiation Oncologists, Surgeons, Pathologists, ECOG, CALGB, NCCTG, NCORP |
Positron Emission Tomography (PET) Imaging of Lung Cancer Response to Therapy in Patients Registered to S9900
| Study Coordinator(s) | Anthony Shields, M.D.,Ph.D., Paul A. Bunn Jr., M.D., Wilbur A. Franklin, M.D. |
| Participants | Members, Medical Oncologists, Pathologists, Surgeons, NCORP |
Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary
| Study Coordinator(s) | Cheryl L. Willman, M.D., Jerald P. Radich, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists, CTSU, Affiliates |
A Phase II Trial of R115777 (NSC #70818) in Patients with Advanced Colorectal Cancer.
| Study Coordinator(s) | Robert P. Whitehead, M.D., John S. Macdonald, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
Evaluation of Topotecan in Resistant and Relapsing Multiple Myeloma, Phase II
| Study Coordinator(s) | Eric H. Kraut, M.D. |
Autologous Stem Cell Transplantation for Patients with Acute Myeloid Leukemia Beyond First Remission: A Randomized Trial of Post-Transplant Therapy with Interleukin-2 Versus Observation Phase III
| Study Coordinator(s) | Alexander Fefer, M.D., Nanette Robinson, M.D., David R. Head, M.D., R. Ellen Magenis, M.D., Cheryl L. Willman, M.D. |
Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma, A BMT Study, Phase III
| Study Coordinator(s) | Alexander Fefer, M.D., John A. Thompson, M.D., Patricia K. Lillis-Hearne, M.D. |
| Participants | Limited Institutions: BMT Members |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required